• Hepatocellular carcinoma
• Immunotherapy
• Liver surgery
• Minimally invasive surgery
• Transplantation

• Humans
• Liver Neoplasms/surgery
• Liver Neoplasms/pathology
• Carcinoma, Hepatocellular/surgery
• Carcinoma, Hepatocellular/pathology
• Hepatectomy/methods
• Liver Transplantation
• Patient Selection
• Robotic Surgical Procedures/methods
• Neoplasm Staging
• Combined Modality Therapy

• The University of Tokyo

• Liver segment
• Portal ramification
• Segmental anatomy
• Three dimensions

• 2019CFB433 Natural Science Foundation of Hubei Province
• CXPJJH11800001-2018306 Hengrui Hepatobiliary and Pancreatic Malignant Tumor Research Fund-Youth Research Fund
• 2018ACA137 Sources of funding: Key project of science and technology in Hubei Province
• WJ2021M108 General Project of Health Commission of Hubei Province
• Y-XD202001-0289 Beijing CSCO Clinical Oncology Research Foundation

• hepatocellular carcinoma
• laparoscopic liver resection
• radiofrequency ablation
• salvage hepatectomy

• Humans
• Carcinoma, Hepatocellular/surgery
• Liver Neoplasms/surgery
• Male
• Female
• Middle Aged
• Hepatectomy/methods
• Aged
• Treatment Outcome
• Length of Stay/statistics & numerical data
• Retrospective Studies
• Postoperative Complications/epidemiology
• Postoperative Complications/etiology

• anatomical liver resection
• early recurrence
• hepatocellular carcinoma
• local recurrence
• survival

• Humans
• Liver Neoplasms/surgery
• Liver Neoplasms/pathology
• Liver Neoplasms/mortality
• Carcinoma, Hepatocellular/surgery
• Carcinoma, Hepatocellular/pathology
• Carcinoma, Hepatocellular/mortality
• Male
• Neoplasm Recurrence, Local/prevention & control
• Female
• Hepatectomy/methods
• Middle Aged
• Retrospective Studies
• Propensity Score
• Aged
• Survival Rate
• Survival Analysis

• Humans
• Carcinoma, Hepatocellular/surgery
• Carcinoma, Hepatocellular/pathology
• Hepatectomy/methods
• Liver/surgery
• Liver Neoplasms/surgery
• Liver Neoplasms/pathology
• Meta-Analysis as Topic

• Indocyanine green
• hepatectomy
• hepatocellular carcinoma
• real-time virtual sonography

• Humans
• Carcinoma, Hepatocellular/diagnostic imaging
• Carcinoma, Hepatocellular/surgery
• Indocyanine Green
• Liver Neoplasms/diagnostic imaging
• Liver Neoplasms/surgery
• Hepatectomy/methods
• Retrospective Studies
• Feasibility Studies
• Neoplasm Recurrence, Local/surgery
• Margins of Excision
• Postoperative Complications/surgery
• Technology

• anatomical hepatectomy
• cavitron ultrasonic surgical aspirator
• liver tumor
• open liver resection
• water-jet scalpel

• anatomical liver resection
• hepatocellular carcinoma
• liver resection
• non-anatomical liver resection

• Humans
• Carcinoma, Hepatocellular
• Liver Neoplasms
• Retrospective Studies
• Hepatectomy/adverse effects
• Propensity Score
• Postoperative Complications/surgery
• Neoplasm Recurrence, Local/surgery

• Hepatocellular carcinoma
• Magnetic resonance imaging
• Morphological classification
• Prediction
• Prognosis

• Humans
• Carcinoma, Hepatocellular/diagnostic imaging
• Carcinoma, Hepatocellular/surgery
• Liver Neoplasms/diagnostic imaging
• Liver Neoplasms/surgery
• Retrospective Studies
• Prognosis
• Hepatectomy
• Magnetic Resonance Imaging/methods

• LBH-Z21179 Heilongjiang Province Postdoctoral Science Foundation
• JJQN2021-07 Harbin Medical University Cancer Hospital Haiyan Funds
• JJZD2022-12 Harbin Medical University Cancer Hospital Haiyan Funds
• LH2022H067 Natural Science Foundation of Heilongjiang Province

• Anatomic resection
• Hepatocellular carcinoma
• Microscopic vascular invasion
• Prognosis
• Survival
• T category

• Diagnosis
• Guidelines
• Hepatocellular carcinoma
• Management

• Laennec's capsule
• elastic fibers
• hepatic vein
• live surgery
• liver

• Natural Science Foundation of Guangdong Province

Recurrent hepatocellular carcinoma (rHCC) is a common outcome after curative treatment. Retreatment for rHCC is recommended, but no guidelines exist.

To compare curative treatments such as repeated hepatectomy (RH), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and liver transplantation (LT) for patients with rHCC after primary hepatectomy by conducting a network meta-analysis (NMA).

From 2011 to 2021, 30 articles involving patients with rHCC after primary liver resection were retrieved for this NMA. The Q test was used to assess heterogeneity among studies, and Egger’s test was used to assess publication bias. The efficacy of rHCC treatment was assessed using disease-free survival (DFS) and overall survival (OS).

From 30 articles, a total of 17, 11, 8, and 12 arms of RH, RFA, TACE, and LT subgroups were collected for analysis. Forest plot analysis revealed that the LT subgroup had a better cumulative DFS and 1-year OS than the RH subgroup, with an odds ratio (OR) of 0.96 (95%CI: 0.31-2.96). However, the RH subgroup had a better 3-year and 5-year OS compared to the LT, RFA, and TACE subgroups. Hierarchic step diagram of different subgroups measured by the Wald test yielded the same results as the forest plot analysis. LT had a better 1-year OS (OR: 1.04, 95%CI: 0.34-03.20), and LT was inferior to RH in 3-year OS (OR: 10.61, 95%CI: 0.21-1.73) and 5-year OS (OR: 0.95, 95%CI: 0.39-2.34). According to the predictive P score evaluation, the LT subgroup had a better DFS, and RH had the best OS. However, meta-regression analysis revealed that LT had a better DFS (P < 0.001) as well as 3-year OS (P = 0.881) and 5-year OS (P = 0.188). The differences in superiority between DFS and OS were due to the different testing methods used.

According to this NMA, RH and LT had better DFS and OS for rHCC than RFA and TACE. However, treatment strategies should be determined by the recurrent tumor characteristics, the patient’s general health status, and the care program at each institution.

• Hepatocellular carcinoma
• Recurrence
• Network meta-analysis
• Curative treatment
• Outcome
• Survival rate

• Hepatocellular carcinoma
• Liver resection
• Recurrent site

• Humans
• Carcinoma, Hepatocellular/surgery
• Carcinoma, Hepatocellular/pathology
• Liver Neoplasms/surgery
• Liver Neoplasms/pathology
• Retrospective Studies
• Neoplasm Recurrence, Local/surgery
• Neoplasm Recurrence, Local/pathology
• Hepatectomy
• Recurrence

• fluorescent cholangiography
• fluorescent navigation
• indocyanine green
• staining

• Humans
• Coloring Agents
• Indocyanine Green/pharmacology
• Cholangiography/methods
• Liver Neoplasms/diagnostic imaging
• Liver Neoplasms/surgery

• Diagnosis
• Guidelines
• Hepatocellular carcinoma
• Management

• Male
• Humans
• Carcinoma, Hepatocellular/diagnostic imaging
• Carcinoma, Hepatocellular/therapy
• Liver Neoplasms/diagnostic imaging
• Liver Neoplasms/therapy
• Hepatitis B, Chronic/complications
• Hepatitis B
• Republic of Korea

• National Cancer Center

• Diagnosis
• Guidelines
• Hepatocellular carcinoma
• Management

• Humans
• Male
• Carcinoma, Hepatocellular/diagnosis
• Carcinoma, Hepatocellular/therapy
• Carcinoma, Hepatocellular/pathology
• Hepatitis B, Chronic/complications
• Liver Neoplasms/diagnosis
• Liver Neoplasms/therapy
• Liver Neoplasms/pathology
• Prevalence
• Republic of Korea/epidemiology

• 2112570-2 National Cancer Center

• hepatocellular carcinoma
• liver resection
• outcomes
• surgery

• Aged
• Carcinoma, Hepatocellular/pathology
• Carcinoma, Hepatocellular/surgery
• Cohort Studies
• Female
• Humans
• Liver Neoplasms/pathology
• Liver Neoplasms/surgery
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Retrospective Studies

Primary liver cancer is the second-most commonly occurring cancer and has resulted in numerous deaths worldwide. Hepatic resection is of two main types, i.e., anatomic resection (AR) and non-anatomic resection (NAR). The oncological outcomes of hepatocellular carcinoma (HCC) patients after AR and NAR are still considered controversial. Therefore, we aimed to compare the impact of AR and NAR on the oncological outcomes of HCC patients with tumor diameters ≤ 5 cm using the propensity score matching method and research-based evidence.

A systematic literature search was conducted. The main outcomes were disease-free survival (DFS), overall survival (OS), intrahepatic recurrence rate, and extrahepatic metastasis rate. Relative risk (RR) was calculated from forest plots and outcomes using random-effects model (REM).

AR significantly improved DFS at 1, 3. and 5 years after surgery, compared to NAR (RR = 1.09, 95% CI = 1.04–1.15, P = 0.0003; RR = 1.16, 95% CI = 1.07–1.27, P = 0.0005; RR = 1.29, 95% CI = 1.07–1.55, P = 0.008). However, both of the difference in DFS at 7 years and OS at 1 and 3 years after AR versus that after NAR were not statistically significant. Nevertheless, the long-term OS associated with AR (5, 7, and 10 years) was superior to that associated with NAR (RR = 1.12, 95% CI = 1.03–1.21, P = 0.01; RR = 1.19, 95% CI = 1.04–1.36, P = 0.01; RR = 1.18, 95% CI = 1.05–1.34, P = 0.008). The difference in the intrahepatic recurrence rate after AR versus that after NAR was not statistically significant, but the extrahepatic metastasis rate after AR was significantly lower than that observed after NAR (RR = 0.61, 95% CI = 0.40–0.94, P = 0.03).

Therefore, AR should be the preferred surgical approach for HCC patients with tumor diameters ≤ 5 cm.

PROSPERO registration number CRD42022330596.

• Anatomic resection
• Hepatocellular carcinoma
• Non-anatomic resection
• Propensity score matching
• Survival

• Anatomic resection
• Hepatocellular carcinoma
• Long-term outcome
• Overall survival
• Radiofrequency ablation

• National Natural Science Foundation of China

Anatomical liver resection is the optimal treatment for patients with resectable hepatocellular carcinoma (HCC). Laparoscopic Couinaud liver segment resection could be performed easily as liver segments could be stained by ultrasound-guided indocyanine green (ICG) injection into the corresponding segment portal vein. Several smaller liver anatomical units (liver watersheds) have been identified (such as S8v, S8d, S4a, and S4b). However, since portal veins of liver watersheds are too thin to be identified under ultrasound, the boundaries of these liver watersheds could not be stained intraoperatively, making laparoscopic resection of these liver watersheds demanding. Digital subtraction angiography (DSA) could identify arteries of liver watersheds with a diameter of less than 2 mm. Yet, its usage for liver watershed staining has not been explored so far.

The aim of this study is to explore the possibility of positive liver watershed staining via trans-arterial ICG injection under DSA examination for navigating laparoscopic watershed-oriented hepatic resection.

We describe, in a step-by-step approach, the application of trans-arterial ICG injection to stain aimed liver watershed during laparoscopic anatomical hepatectomy. The efficiency and safety of the technique are illustrated and discussed in comparison with the laparoscopic anatomical liver resection via ultrasound-guided liver segment staining.

Eight of 10 HCC patients received successful trans-arterial liver watershed staining. The success rate of the trans-artery staining approach was 80%, higher than that of the ultrasound-guided portal vein staining approach (60%). Longer surgical duration was found in patients who underwent the trans-artery staining approach (305.3 ± 23.2 min vs. 268.4 ± 34.7 min in patients who underwent the ultrasound-guided portal vein staining approach, p = 0.004). No significant difference was found in major morbidity, reoperation rate, hospital stay duration, and 30-day and 90-day mortality between the 2 groups.

Trans-arterial ICG staining is safe and feasible for staining the aimed liver watershed, navigating watershed-oriented hepatic resection under fluorescence laparoscopy for surgeons.

It is generally accepted that non-anatomical resection (NAR) in colorectal liver metastasis (CRLM) has comparable safety and efficacy compared to anatomical resection (AR); however, there are reports that AR may have better outcomes in KRAS mutated CRLM. This study aimed to determine the effects of KRAS mutations and surgical techniques on survival outcomes in CRLM patients.

Two hundred fifty patients who underwent hepatic resection of CRLM with known KRAS mutational status between 2007 and 2018 were analyzed. A total of 94 KRAS mutated CRLM and 156 KRAS wild-type CRLM were subdivided by surgical approach and compared for short- and long-term outcomes.

In both KRAS wild-type and mutated type, there was no difference in estimated blood loss, postoperative complications, and 30-day mortality. There was no difference in disease-free survival (DFS) between AR and NAR in both groups (p = 0.326, p = 0.954, respectively). Finally, there was no difference in intrahepatic DFS between AR and NAR groups in both the KRAS groups (p = 0.165, p = 0.516, respectively).

The presence of KRAS mutation may not be a significant factor when deciding the approach in simultaneous resection of CRLM.

Recent studies have suggested that periportal location of percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is considered as one of the independent risk factors for local tumor progression (LTP). However, the long-term therapeutic outcomes of percutaneous RFA as the first-line therapy for single periportal HCCand corresponding impacts on tumor recurrence or progression are still unclear.

From February 2011 to October 2020, a total of 233 patients with single nodular HCC ≤ 5 cm who underwent RFA ± transarterial chemoembolization (TACE) as first-line therapy was enrolled and analyzed, including 56 patients in the periportal group and 177 patients in the nonperiportal group. The long-term therapeutic outcomes between the two groups were compared, risk factors of tumor recurrence or progression were evaluated.

The LTP rates at 1, 3, and 5 years were significantly higher in the periportal group than those in the nonperiportal group (15.7, 33.7, and 46.9% vs 6.0, 15.7, and 28.7%, respectively, P = 0.0067). The 1-, 3- and 5-year overall survival (OS) rates in the periportal group were significantly worse than those in the nonperiportal group (81.3, 65.1 and 42.9% vs 99.3, 90.4 and 78.1%, respectively, P<0.0001). In the subgroup of single HCC ≤ 3 cm, patients with periportal HCC showed significantly worse LTP P = 0.0006) and OS (P<0.0001) after RFA than patients with single nonperiportal HCC; The univariate and multivariate analyses revealed that tumor size, periportal HCC and AFP ≥ 400ug/ml were independent prognostic factors for tumor progression after RFA. Furthermore, patients with single periportal HCC had significantly higher risk for IDR(P = 0.0012), PVTT(P<0.0001) and extrahepatic recurrence(P = 0.0010) after RFA than those patients with single nonperiportal HCC. .

The long-term therapeutic outcomes of RFA as the first-line therapy for single periportal HCC were worse than those for single nonperiportal HCC, an increased higher risk of tumor recurrence or progression after RFA was significantly associated with periportal HCC.

The online version contains supplementary material available at 10.1186/s40644-021-00442-2.

• Hepatocellular carcinoma (HCC)
• Periportal
• Radiofrequency ablation (RFA)
• Therapeutic outcomes
• Tumor progression
• Tumor recurrence

• Precise hepatectomy
• meta-analysis
• primary liver cancer
• traditional hepatectomy

• Chemotherapy
• Hepatectomy
• Hepatocellular carcinoma
• Surgery

The long-term survival of patients with solitary hepatocellular carcinoma (HCC) following anatomical resection (AR) vs non-anatomical resection (NAR) is still controversial. It is necessary to investigate which approach is better for patients with solitary HCC.

To compare perioperative and long-term survival outcomes of AR and NAR for solitary HCC.

We performed a comprehensive literature search of PubMed, Medline (Ovid), Embase (Ovid), and Cochrane Library. Participants of any age and sex, who underwent liver resection, were considered following the following criteria: (1) Studies reporting AR vs NAR liver resection; (2) Studies focused on primary HCC with a solitary tumor; (3) Studies reporting the long-term survival outcomes (> 5 years); and (4) Studies including patients without history of preoperative treatment. The main results were overall survival (OS) and disease-free survival (DFS). Perioperative outcomes were also compared.

A total of 14 studies, published between 2001 and 2020, were included in our meta-analysis, including 9444 patients who were mainly from China, Japan, and Korea. AR was performed on 4260 (44.8%) patients. The synthetic results showed that the 5-year OS [odds ratio (OR): 1.19; P < 0.001] and DFS (OR: 1.26; P < 0.001) were significantly better in the AR group than in the NAR group. AR was associated with longer operating time [mean difference (MD): 47.08; P < 0.001], more blood loss (MD: 169.29; P = 0.001), and wider surgical margin (MD = 1.35; P = 0.04) compared to NAR. There was no obvious difference in blood transfusion ratio (OR: 1.16; P = 0.65) or postoperative complications (OR: 1.24, P = 0.18).

AR is superior to NAR in terms of long-term outcomes. Thus, AR can be recommended as a reasonable surgical option in patients with solitary HCC.

• Hepatocellular carcinoma
• Anatomical resection
• Non-anatomical resection
• Meta-analysis
• Systematic review
• Solitary tumor

• Anatomical resection
• Hepatocellular carcinoma
• Propensity score matching

• Anatomical resection
• Comparison
• Hepatocellular carcinoma
• Recurrence mechanism

• cholangiocarcinoma
• hepatectomy
• hepatitis viruses
• prognosis

• Anatomical resection
• Japan
• Taiwan
• disease-free survival
• hepatocellular carcinoma
• non-anatomical resection
• overall survival
• propensity score matched analysis

Laparoscopic anatomic hepatectomy (LAH) has gradually become a routine surgical procedure. However, how to expose the whole hepatic vein and avoid the hepatic vein laceration is still a challenge because of the caudate lobe, particularly in right hepatectomy. We adopted a dorsal approach combined with Glissionian appraoch to perform laparoscopic right anatomic hepatectomy (LRAH).

Twenty patients who underwent LRAH from January 2017 to November 2018 were retrospectively analysed. Of these patients, seven patients underwent laparoscopic right hemihepatectomy (LRH group), seven patients who underwent laparoscopic right posterior hepatectomy (LRPH group), and six patients who underwent laparoscopic hepatectomy for segment 7 (LS7 group). The paracaval portion of caudate lobe could be transected firstly through dorsal approach and the corresponding major hepatic vein could be exposed from its root to the peripheral branches safely. Due to exposure along the major hepatic vein trunk, the remaining liver parenchyma could be quickly transected from dorsal to cranial side.

The mean age of the patients was 53.8 years and the male: female ratio was 8:12. The median operation time was 306.0 ± 58.2 min and the mean estimated volume of blood loss was 412.5 ± 255.4 mL. The mean duration of postoperative hospital stay was 10.2 days. The mean Pringle maneuver time was 64.8 ± 27.7 min. Five patients received transfusion of 2–4 U of red blood cells. Two patients suffered from transient hepatic dysfunction and one suffered from pleural effusion. None of the patients underwent conversion to an open procedure. The operative duration, volume of the blood loss, Pringle maneuver time, and postoperative hospital stay duration did not differ significantly among the LRH, LRPH, and LS7 groups (P > 0.05).

Dorsal approach combined with Glissonian approach for right lobe is feasible and effective in laparoscopic right anatomic liver resections.

The online version contains supplementary material available at 10.1186/s12876-021-01726-4.

• Dorsal approach
• Hepatectomy
• Laparoscopy
• Surgical procedure

Curative resection is recommended for patient with early stage hepatocellular carcinoma (HCC), however, the prognosis is limited by high recurrence rate. This study was to investigate liver stiffness (LS) and metabolic factor in prediction of HCC recurrence for patients with early stage HCC who had undergone curative resection. Consecutive patients with suspicion of HCC who had undergone curative resection were prospectively enrolled. Transient elastography was performed to determine LS pre-operatively. The demographics, clinical characteristics and histological findings were recorded. All patients were followed up regularly until recurrence, death or last visit. Ninety-four patients with early stage HCC were enrolled. LS positively correlated with fibrosis stage (r = 0.666). In a median follow-up of 3.2 years, forty patients developed recurrences including 22 recurrences after 1-year post resection. The 5-year cumulative recurrence rate was 44.2%. LS was the independent factor associated with recurrence. Patients with LS > 8.5 kPa had higher 5-year cumulative recurrence rate (59.8% vs 25.1%, p = 0.007). For the prediction of recurrence after 1-year post resection, LS > 8.5 kPa (hazard ratio 2.72) and homeostatic model assessment for insulin resistance index (HOMA-IR) (hazard ratio 1.24) were independent factors in multivariate analysis. Those patients with both LS > 8.5 kPa and HOMA-IR > 2.3 had the highest recurrence rate after 1-year post resection.

Surgery with fluorescence equipment has improved to treat the malignant viscera, including hepatobiliary and pancreatic neoplasms. In both open and minimally invasive surgeries, optical imaging using near-infrared (NIR) fluorescence is used to assess anatomy and function in real time. Here, we review a variety of publications related to clinical applications of NIR fluorescence imaging in liver surgery. We have developed a novel nanoparticle (indocyanine green lactosome) that is biocompatible and can be used for imaging cancer tissues and also as a drug delivery system. To date, stable particles are formed in blood and have an ~10–20 h half-life. Particles labeled with a NIR fluorescent agent have been applied to cancer tissues by the enhanced permeability and retention effect in animals. Furthermore, this article reviews recent developments in photodynamic therapy with NIR fluorescence imaging, which may contribute and accelerate the innovative treatments for liver tumors.

• indocyanine green lactosome
• liver surgery navigation
• liver tumors
• near-infrared fluorescence imaging
• photodynamic therapy

• anatomical resection
• circulating tumor cells
• hepatocellular carcinoma
• neoangiogenesis
• protumorigenic niche
• resection margin
• tumor microenvironment

• Carcinoma, Hepatocellular/surgery
• Hepatectomy
• Humans
• Liver Neoplasms/surgery
• Neoplasm Recurrence, Local
• Tumor Microenvironment

Intrahepatic cholangiocarcinoma (IHCC) is the second most common primary hepatic malignant tumor after hepatocellular carcinoma (HCC). The prevalence of lymph node metastases (LNM) detected at surgery for IHCC has been reported as 25–50%, and lymph node metastasis is known to be significantly associated with poor survival outcomes. However, the oncologic value of lymph node dissection in resected IHCC is still controversial. According to the present Korea–Japan international collaborative study, it was found that surgical retrieval of more than four lymph nodes (≥4 LNs) could improve survival outcome in resected IHCC with LNM. Based on preoperatively detectable parameters, a nomogram was established to predict LNM to suggest tailored intraoperative LN management in patients with IHCC. Further prospective research is needed to validate the present surgical strategy in resected IHCC.

Background: This study was performed to investigate the oncologic role of lymph node (LN) management and to propose a surgical strategy for treating intrahepatic cholangiocarcinoma (IHCC). Methods: The medical records of patients with resected IHCC were retrospectively reviewed from multiple institutions in Korea and Japan. Short-term and long-term oncologic outcomes were analyzed according to lymph node metastasis (LNM). A nomogram to predict LNM in treating IHCC was established to propose a surgical strategy for managing IHCC. Results: A total of 1138 patients were enrolled. Of these, 413 patients underwent LN management and 725 did not. A total of 293 patients were found to have LNM. The No. 12 lymph node (36%) was the most frequent metastatic node, and the No. 8 lymph node (21%) was the second most common. LNM showed adverse long-term oncologic impact in patients with resected IHCC (14 months, 95% CI (11.4–16.6) vs. 74 months, 95% CI (57.2–90.8), p < 0.001), and the number of LNM (0, 1–3, 4≤) was also significantly related to negative oncologic impacts in patients with resected IHCC (74 months, 95% CI (57.2–90.8) vs. 19 months, 95% CI (14.4–23.6) vs. 11 months, 95% CI (8.1–13.8)), p < 0.001). Surgical retrieval of more than four (≥4) LNs could improve the survival outcome in resected IHCC with LNM (13 months, 95% CI (10.4–15.6)) vs. 30 months, 95% CI (13.1–46.9), p = 0.045). Based on preoperatively detectable parameters, a nomogram was established to predict LNM according to the tumor location. The AUC was 0.748 (95% CI: 0.706–0.788), and the Hosmer and Lemeshow goodness of fit test showed p = 0.4904. Conclusion: Case-specific surgical retrieval of more than four LNs is required in patients highly suspected to have LNM, based on a preoperative detectable parameter-based nomogram. Further prospective research is needed to validate the present surgical strategy in resected IHCC.

• cholangiocarcinoma
• lymph nodes
• metastasis
• nomograms

• Anatomic resection
• HCC
• Hepatocarcinoma
• Meta-analysis
• Non-anatomic resection
• Parenchyma sparing resection
• Survival

• gadolinium DTPA
• hepatectomy
• hepatocellular carcinoma
• magnetic resonance imaging
• surgical oncology

• Carcinoma, Hepatocellular/diagnostic imaging
• Carcinoma, Hepatocellular/surgery
• Contrast Media
• Gadolinium DTPA
• Humans
• Liver Neoplasms/diagnostic imaging
• Liver Neoplasms/surgery
• Magnetic Resonance Imaging
• Neoplasm Recurrence, Local/diagnostic imaging
• Retrospective Studies